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Current trends in medical services and health economy
clearly demonstrate that without innovation in health-
care, e.g. in years around 2030 the prevalence of
Diabetes mellitus will reach the dimension of a half of
billion of affected people worldwide additionally bur-
dened with a spectrum of secondary complications
(blindness, cancer, cardiovascular and neurodegenerative
diseases) and enormous economical burden linked to
the required treatments. In the same period of time,
neurodegenerative pathologies (Alzheimer’s and Parkin-
son’s diseases, glaucoma and macular degeneration, etc.)
can reach more than 30% of global disease burden. The
pandemic of some cancer types is evident for both chil-
dren and adults, men and women, developed and devel-
oping countries altogether linked to the enormously
increasing economical pressure within healthcare sys-
tems. In contrast, effective utilisation of advanced early/
predictive diagnostics, targeted prevention and medical
services tailored to the person could enable a significant
portion of population to reach the 100-year age limit
remaining vibrant in excellent physical and mental health
as actively contributing members of society. This task
requires intelligent political regulations and creation of
new guidelines to advance current healthcare systems.
Targeted preventive measures should be well regulated
by innovative reimbursement programmes introduced by
policy-makers. This is considered as preventive medicine
of future to effective costs. The overall concept in the
field is conducted by the “European Association for Pre-
dictive, Preventive and Personalised Medicine” (EPMA).
Optimistic versus Pessimistic Scenario depends much
on diagnostic, preventive and treatment approaches
which healthcare will preferably adopt in the near
future. Global research and implementation programmes
in bio/medicine, communication among scientific socie-
ties, healthcare-providers, policy-makers, educators and
organised patient groups and, finely, a consolidation of
professional groups in the branch will play a decisive
role to drive the situation in favour of one of two sce-
narios over the next 5-10 years.
The PPPM related legislation would play a key role in the
adequate regulation for the positive scenario. The stake-
holders realise that without a correct juristic platform in
healthcare, the global market cannot be created for a spec-
trum of PPPM related technological innovations and
advances medical services; global industry is not motivated
to bring corresponding products to the market; patenting
of PPPM related innovation remains unrequested that alto-
gether leads to a stagnation of the validation of novel dis-
ease specific biomarkers and unutilised research data (see
Figure 1). Indeed, our current large-scaled project (incl. all
countries of the European Union and others worldwide)
supported by the Alexander von Humboldt-Foundation has
clearly demonstrated a strongly handicapped process of the
current policy making in healthcare systems, when the pro-
fessional position and knowledge accumulated by the
healthcare providers and relevant scientific institutions
remains separated from / not requested by the legislation
responsible bodies. PPPM related legislation is the central
issue of the EPMA Summit in the EU-Parliament, Brussels
on September 19th 2013 and concomitant consultation of
our experts group with the legislation relevant bodies in the
Europe and worldwide. Issue-related innovative European
and intercontinental projects, which EPMA introduces for
further consideration at the EU-Commission, European
Parliament and UNO are elaborated by the consortium of
the world-leading professionals and professional groups
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Figure 1 As long as the PPPM related legislation does not promote the implementation of innovative technologies in healthcare systems, the
stakeholders are decoupled from each other and the concomitant activities are blocked.
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